The Broad Institute called UC's new legal strategy "deeply unfortunate" and called on the university to "move beyond litigation."
As MPEG LA tries to complete its larger CRISPR IP patent pool, smaller license agreements continue and a mini-pool has emerged between key players.
The process challenges claims made in certain UC Berkeley patents on the use of CRISPR-Cas9 to edit eukaryotic genomes.
The Patent Trial and Appeal Board has denied Foundation Medicine's request for Inter Partes review.
The firm's CEO Kevin Ness said confirmation of MAD7's editing activity in human HEK293T cells shows the potential for Inscripta's technology.
Reuters reports that the panel hearing the CRISPR gene editing patent case appears split.
The Broad Institute also announced announced a setback in proceedings over a CRISPR patent application filed in Europe.
Michelle Lee, the director of the United States Patent and Trademark Office, has resigned, IP Watchdog reports.
The University of California is appealing the recent CRISPR/Cas9 patent decision.
The Broad Institute has a shot to end the dispute by early 2017 but the more likely outcome is that the parties will argue over whether to fracture the CRISPR IP estate.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.